U.S. markets closed

Cryoport, Inc. (CYRX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
23.07+0.57 (+2.53%)
At close: 04:00PM EST
23.45 +0.38 (+1.65%)
After hours: 07:12PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close22.50
Bid23.08 x 900
Ask23.13 x 800
Day's Range22.28 - 23.26
52 Week Range15.63 - 45.36
Avg. Volume555,145
Market Cap1.13B
Beta (5Y Monthly)1.24
PE Ratio (TTM)N/A
EPS (TTM)-6.19
Earnings DateFeb 22, 2023 - Feb 27, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est30.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for CYRX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • CryoPort, Inc.
    BLFS: What does Argus have to say about BLFS?BIOLIFE SOLUTIONS INC has an Investment Rating of HOLD; a target price of $26.000000; an Industry Subrating of High; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.
    Fair Value
    Economic Moat
    4 days agoArgus Research
View more
  • Zacks

    Syneos Health (SYNH) Signs New Partnership With Cryoport

    Syneos Health (SYNH) inks a partnership with Cryoport to deliver seamless integration and insights for key services for cell and gene trial operations to biopharmaceutical customers.

  • PR Newswire

    Cryoport Announces New Strategic Partnership with Syneos Health to Advance Cell & Gene Therapies

    Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport"), a leading global provider of innovative temperature-controlled supply chain solutions to the life sciences industry focused on the pharmaceutical and cell and gene therapy markets, today announced a new strategic partnership with Syneos Health® (NASDAQ: SYNH), the only fully integrated biopharmaceutical solutions organization purpose-built to accelerate customer success. Both Cryoport and Syneos Health are world leading solutions companies with deep ex

  • PR Newswire

    Cryoport to Present at the J.P. Morgan 41st Annual Healthcare Conference

    Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced that Jerrell Shelton, the Company's Chief Executive Officer, will be presenting at the J.P. Morgan 41st Annual Healthcare conference, taking place from January 9 - 12, 2023 in San Francisco, CA. Mr. Shelton will be presenting on Thursday, January 12, 2023, at 8:15 a.m. PT (11:15 a.m. ET). Additionally, Mr. Shelton, Robert St